Potential for lasting change in use of health tech post-Covid-19
InfoFlex technology supports innovations in healthcare provision
Assisting our NHS customers with Covid-19 tracking
InfoFlex supports NHS with data collection and reporting
InfoFlex Covid-19 Design
InfoFlex COVID-19 design to help you configure a data capture, reporting and alerting tool
InfoFlex supports East Kent and Medway Cancer Alliance
In their Spring newsletter, the East Kent and Medway Cancer Alliance reports on becoming the second highest performing cancer alliance in the country in terms of meeting the national standard for 62-day urgent referral to treatment.
Coronavirus preparedness
CIMS has a certified Business Continuity Plan in place to meet the potential impact of the Coronavirus.
Predictions for Health Tech in 2020
Making integrated care a reality.
InfoFlex in the press – Improving rheumatology patient care
InfoFlex helps to improve the experience of rheumatology patients.
Turning a paper process digital
How InfoFlex can help digitise paper-based processes
InfoFlex respond to the NHSX report: Listening to Digital Health Innovators
InfoFlex, along with other healthcare industry leaders, respond to the NHSX report, Listening to Digital Health Innovators.
What are the main challenges in healthcare tech?
InfoFlex CEO offers his response to the question HTN (Health Tech Newspaper) asked industry leaders recently.
InfoFlex CEO attends influential Public Policy Projects round table: Turning Policy into Practice: Medical and digital technology and the NHS long-term plan
This May, Marc Warburton, Chief Executive of InfoFlex, attended the Public Policy Projects round table in central London.
CIMS works with researchers at Warwick Medical School and PCUK to develop Chat-P, a prostate specific eHNA and Care Planning tool.
InfoFlex was chosen as the platform on which to develop a prostate specific eHNA and Care Planning tool as part of research into the feasibility and acceptability of the use of technology in a supported self-management programme.